Nuvation Bio Inc
NYSE:NUVB

  • LAST PRICE
    3.0400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.1100/ 28
  • Ask / Lots
    3.5000/ 1
  • Open / Previous Close
    3.0000 / 3.0400
  • Day Range
    2.9000
    3.0400
  • 52 Week Range
    0.9500
    4.1598
  • Volume
    1,882,710

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
NUVB
Nuvation Bio Inc
741.5M
-9.7x
---
PRME
Prime Medicine Inc
749.0M
-2.7x
---
DNTH
Dianthus Therapeutics Inc
749.0M
-7.6x
---
CRGX
CARGO Therapeutics Inc
713.8M
-5.1x
---
SPRY
ARS Pharmaceuticals Inc
798.4M
-14.7x
---
CATX
Perspective Therapeutics Inc
694.0M
-5.9x
---
As of 2024-06-26

Company Information

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Contact Information

Headquarters
357 Tehama Street, Floor 3SAN FRANCISCO, CA, United States 94103
Phone
415-754-3517
Fax
302-636-5454

Executives

Independent Chair of the Board
Daniel Welch
President, Chief Executive Officer, Founder, Director
David Hung
Principal Financial and Accounting Officer, Vice President - Finance
Moses Makunje
Chief Executive Officer of AnHeart Therapeutics and Director
Junyuan Wang
Chief People Officer
Stacy Markel

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$741.5M
Revenue (TTM)
$0.00
Shares Outstanding
247.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.41
EPS
$-0.31
Book Value
$2.76
P/E Ratio
-9.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.